The company continues to expect to end 2007 with between $100 million and $110 million of cash, cash equivalents and marketable securities. Included within this guidance are $20 million in regulatory approval milestone payments from Novartis Pharma AG related to TYZEKA/SEBIVO (telbivudine 600mg tablets), $10 million of which was received in April 2007. The remaining milestone payment is related to regulatory approval of telbivudine in the European Union, which the company anticipates receiving in the second quarter of this year.
Market Data 
Markets 
AI
